Future Science Group
Browse
supplementary data.docx (69.13 kB)

Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults: Supplementary data

Download (69.13 kB)
dataset
posted on 2023-07-20, 10:48 authored by Ataru Igarashi, Kanae Togo, Yasuhiro Kobayashi, Kazumasa Kamei, Naohiro Yonemoto, Naruhiko Ishiwada

Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods:

Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length

of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults

(OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among

those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDVinfant

(n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged

<1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in

JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and

OAs.

Funding

This study was supported by Pfizer Japan Inc.

History

Usage metrics

    Future Virology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC